» Articles » PMID: 28034071

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Abstract

Purpose Double-hit lymphomas (DHLs) and double-expressor lymphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with poor outcomes after standard chemoimmunotherapy. Data are limited regarding outcomes of patients with relapsed or refractory (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT). We retrospectively studied the prognostic impact of DEL and DHL status on ASCT outcomes in patients with rel/ref DLBCL. Methods Patients with chemotherapy-sensitive rel/ref DLBCL who underwent ASCT at two institutions and in whom archival tumor material was available were enrolled. Immunohistochemistry for MYC, BCL2, and BCL6 and fluorescence in situ hybridization (FISH) for MYC were performed. In cases with MYC rearrangement or copy gain, FISH for BCL2 and BCL6 was also performed. Results A total of 117 patients were included; 44% had DEL and 10% had DHL. DEL and DHL were associated with inferior progression-free survival (PFS), and DHL was associated with poorer overall survival (OS). The 4-year PFS in patients with DEL compared with those with non-DEL was 48% versus 59% ( P = .049), and the 4-year OS was 56% versus 67% ( P = .10); 4-year PFS in patients with DHL compared with those with non-DHL was 28% versus 57% ( P = .013), and 4-year OS was 25% versus 61% ( P = .002). The few patients with concurrent DEL and DHL had a poor outcome (4-year PFS, 0%). In multivariable models, DEL and DHL were independently associated with inferior PFS, whereas DHL and partial response ( v complete response) at transplant were associated with inferior OS. Conclusion DEL and DHL are both associated with inferior outcomes after ASCT in patients with rel/ref DLBCL. Although ASCT remains a potentially curative approach, these patients, particularly those with DHL, are a high-risk subset who should be targeted for investigational strategies other than standard ASCT.

Citing Articles

Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLA.

Kurz K, Steinlein S, Kreuz M, Ziepert M, Staiger A, Barth T Hemasphere. 2025; 9(3):e70093.

PMID: 40060117 PMC: 11888124. DOI: 10.1002/hem3.70093.


Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.

Gong I, Tran D, Saibil S, Laister R, Kuruvilla J Hemasphere. 2024; 8(8):e130.

PMID: 39175824 PMC: 11339649. DOI: 10.1002/hem3.130.


Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma.

Liu P, Hang X, Li J, Zhao L, Liu W, Ji J Am J Cancer Res. 2024; 14(6):2921-2933.

PMID: 39005667 PMC: 11236771. DOI: 10.62347/GIIR3351.


Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.

Wu C, Chen S, Wu Z, Xue J, Zhang W, Wang S J Cancer Res Clin Oncol. 2024; 150(2):98.

PMID: 38381215 PMC: 10881688. DOI: 10.1007/s00432-024-05615-7.


Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.

Ip A, Mutebi A, Wang T, Jun M, Kalsekar A, Navarro F Adv Ther. 2024; 41(3):1226-1244.

PMID: 38302846 PMC: 10879405. DOI: 10.1007/s12325-023-02775-9.


References
1.
Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S . MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98(10):1554-62. PMC: 3789460. DOI: 10.3324/haematol.2013.086173. View

2.
Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, Chiba S . MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2013; 54(10):2149-54. DOI: 10.3109/10428194.2013.771398. View

3.
Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

4.
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch D, Trneny M . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184-90. PMC: 3664033. DOI: 10.1200/JCO.2010.28.1618. View

5.
Snuderl M, Kolman O, Chen Y, Hsu J, Ackerman A, Dal Cin P . B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010; 34(3):327-40. PMC: 3152212. DOI: 10.1097/PAS.0b013e3181cd3aeb. View